Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Nestorone® as a Novel Progestin for Nonoral Contraception: Structure-Activity Relationships and Brain Metabolism Studies.

Kumar N, Fagart J, Liere P, Mitchell SJ, Knibb AR, Petit-Topin I, Rame M, El-Etr M, Schumacher M, Lambert JJ, Rafestin-Oblin ME, Sitruk-Ware R.

Endocrinology. 2017 Jan 1;158(1):170-182. doi: 10.1210/en.2016-1426.

2.

Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.

Amazit L, Le Billan F, Kolkhof P, Lamribet K, Viengchareun S, Fay MR, Khan JA, Hillisch A, Lombès M, Rafestin-Oblin ME, Fagart J.

J Biol Chem. 2015 Sep 4;290(36):21876-89. doi: 10.1074/jbc.M115.657957. Epub 2015 Jul 22.

3.

Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors.

Petit-Topin I, Fay M, Resche-Rigon M, Ulmann A, Gainer E, Rafestin-Oblin ME, Fagart J.

J Steroid Biochem Mol Biol. 2014 Oct;144 Pt B:427-35. doi: 10.1016/j.jsbmb.2014.08.008. Epub 2014 Sep 6.

PMID:
25204619
4.

A structural explanation of the effects of dissociated glucocorticoids on glucocorticoid receptor transactivation.

Dezitter X, Fagart J, Taront S, Fay M, Masselot B, Hétuin D, Formstecher P, Rafestin-Oblin ME, Idziorek T.

Mol Pharmacol. 2014 Feb;85(2):226-36. doi: 10.1124/mol.113.085860. Epub 2013 Nov 13.

PMID:
24225022
5.

A new strategy for selective targeting of progesterone receptor with passive antagonists.

Khan JA, Tikad A, Fay M, Hamze A, Fagart J, Chabbert-Buffet N, Meduri G, Amazit L, Brion JD, Alami M, Lombès M, Loosfelt H, Rafestin-Oblin ME.

Mol Endocrinol. 2013 Jun;27(6):909-24. doi: 10.1210/me.2012-1328. Epub 2013 Apr 11.

6.

Mineralocorticoid receptor mutations and a severe recessive pseudohypoaldosteronism type 1.

Hubert EL, Teissier R, Fernandes-Rosa FL, Fay M, Rafestin-Oblin ME, Jeunemaitre X, Metz C, Escoubet B, Zennaro MC.

J Am Soc Nephrol. 2011 Nov;22(11):1997-2003. doi: 10.1681/ASN.2011030245. Epub 2011 Sep 8.

7.

Structural determinants of ligand binding to the mineralocorticoid receptor.

Huyet J, Pinon GM, Fay MR, Rafestin-Oblin ME, Fagart J.

Mol Cell Endocrinol. 2012 Mar 24;350(2):187-95. doi: 10.1016/j.mce.2011.07.035. Epub 2011 Jul 25. Review.

PMID:
21820032
8.

Mineralocorticoid receptor mutations differentially affect individual gene expression profiles in pseudohypoaldosteronism type 1.

Fernandes-Rosa FL, Hubert EL, Fagart J, Tchitchek N, Gomes D, Jouanno E, Benecke A, Rafestin-Oblin ME, Jeunemaitre X, Antonini SR, Zennaro MC.

J Clin Endocrinol Metab. 2011 Mar;96(3):E519-27. doi: 10.1210/jc.2010-1486. Epub 2010 Dec 15.

PMID:
21159846
9.

Steroid profiling in preeclamptic women: evidence for aromatase deficiency.

Hertig A, Liere P, Chabbert-Buffet N, Fort J, Pianos A, Eychenne B, Cambourg A, Schumacher M, Berkane N, Lefevre G, Uzan S, Rondeau E, Rozenberg P, Rafestin-Oblin ME.

Am J Obstet Gynecol. 2010 Nov;203(5):477.e1-9. doi: 10.1016/j.ajog.2010.06.011. Epub 2010 Aug 5.

PMID:
20691412
10.

A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.

Fagart J, Hillisch A, Huyet J, Bärfacker L, Fay M, Pleiss U, Pook E, Schäfer S, Rafestin-Oblin ME, Kolkhof P.

J Biol Chem. 2010 Sep 24;285(39):29932-40. doi: 10.1074/jbc.M110.131342. Epub 2010 Jul 22.

11.

Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins.

Petit-Topin I, Turque N, Fagart J, Fay M, Ulmann A, Gainer E, Rafestin-Oblin ME.

Mol Pharmacol. 2009 Jun;75(6):1317-24. doi: 10.1124/mol.108.054312. Epub 2009 Mar 16.

PMID:
19289570
12.

Aldosterone activates NF-kappaB in the collecting duct.

Leroy V, De Seigneux S, Agassiz V, Hasler U, Rafestin-Oblin ME, Vinciguerra M, Martin PY, Féraille E.

J Am Soc Nephrol. 2009 Jan;20(1):131-44. doi: 10.1681/ASN.2008020232. Epub 2008 Nov 5.

13.

Structural basis of spirolactone recognition by the mineralocorticoid receptor.

Huyet J, Pinon GM, Fay MR, Fagart J, Rafestin-Oblin ME.

Mol Pharmacol. 2007 Sep;72(3):563-71. Epub 2007 Jun 14.

PMID:
17569793
14.

The synthetic androgen methyltrienolone (r1881) acts as a potent antagonist of the mineralocorticoid receptor.

Takeda AN, Pinon GM, Bens M, Fagart J, Rafestin-Oblin ME, Vandewalle A.

Mol Pharmacol. 2007 Feb;71(2):473-82. Epub 2006 Nov 14.

PMID:
17105867
15.

Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension.

Fagart J, Huyet J, Pinon GM, Rochel M, Mayer C, Rafestin-Oblin ME.

Nat Struct Mol Biol. 2005 Jun;12(6):554-5. Epub 2005 May 22.

PMID:
15908963
16.

The Met852 residue is a key organizer of the ligand-binding cavity of the human mineralocorticoid receptor.

Fagart J, Seguin C, Pinon GM, Rafestin-Oblin ME.

Mol Pharmacol. 2005 May;67(5):1714-22. Epub 2005 Feb 16.

PMID:
15716462
17.

Dehydroepiandrosterone and its 7-hydroxylated metabolites do not interfere with the transactivation and cellular trafficking of the glucocorticoid receptor.

Muller C, Cluzeaud F, Pinon GM, Rafestin-Oblin ME, Morfin R.

J Steroid Biochem Mol Biol. 2004 Dec;92(5):469-76. Epub 2004 Dec 19.

PMID:
15698552
18.

11-deoxycorticosterone is a potent agonist of the rainbow trout (Oncorhynchus mykiss) mineralocorticoid receptor.

Sturm A, Bury N, Dengreville L, Fagart J, Flouriot G, Rafestin-Oblin ME, Prunet P.

Endocrinology. 2005 Jan;146(1):47-55. Epub 2004 Oct 14.

PMID:
15486226
19.

[Agonists and antagonists of mineralocorticoids. The relation between structure and activity].

Fagart J, Pinon GM, Rafestin-Oblin ME.

Ann Cardiol Angeiol (Paris). 2004 Jun;53(3):154-7. Review. French.

PMID:
15291173
20.

Identification of steroid ligands able to inactivate the mineralocorticoid receptor harboring the S810L mutation responsible for a severe form of hypertension.

Pinon GM, Fagart J, Souque A, Auzou G, Vandewalle A, Rafestin-Oblin ME.

Mol Cell Endocrinol. 2004 Mar 31;217(1-2):181-8.

PMID:
15134816
21.

Conditional gene expression in renal collecting duct epithelial cells: use of the inducible Cre-lox system.

Ouvrard-Pascaud A, Puttini S, Sainte-Marie Y, Athman R, Fontaine V, Cluzeaud F, Farman N, Rafestin-Oblin ME, Blot-Chabaud M, Jaisser F.

Am J Physiol Renal Physiol. 2004 Jan;286(1):F180-7. Epub 2003 Aug 19.

22.

Evidence for two distinct functional glucocorticoid receptors in teleost fish.

Bury NR, Sturm A, Le Rouzic P, Lethimonier C, Ducouret B, Guiguen Y, Robinson-Rechavi M, Laudet V, Rafestin-Oblin ME, Prunet P.

J Mol Endocrinol. 2003 Aug;31(1):141-56.

PMID:
12914532
23.

Glucocorticoid metabolism by 11-beta hydroxysteroid dehydrogenase type 2 modulates human mineralocorticoid receptor transactivation activity.

Bocchi B, Fagart J, Cluzeaud F, Fay M, Rafestin-Oblin ME, Farman N.

J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):239-44.

PMID:
12711009
24.

The severe form of hypertension caused by the activating S810L mutation in the mineralocorticoid receptor is cortisone related.

Rafestin-Oblin ME, Souque A, Bocchi B, Pinon G, Fagart J, Vandewalle A.

Endocrinology. 2003 Feb;144(2):528-33.

PMID:
12538613
25.

11beta-hydroxyprogesterone acts as a mineralocorticoid agonist in stimulating Na+ absorption in mammalian principal cortical collecting duct cells.

Rafestin-Oblin ME, Fagart J, Souque A, Seguin C, Bens M, Vandewalle A.

Mol Pharmacol. 2002 Dec;62(6):1306-13.

PMID:
12435797
26.

Multiple aspects of mineralocorticoid selectivity.

Farman N, Rafestin-Oblin ME.

Am J Physiol Renal Physiol. 2001 Feb;280(2):F181-92. Review.

27.

A single amino acid mutation of ala-773 in the mineralocorticoid receptor confers agonist properties to 11beta-substituted spirolactones.

Auzou G, Fagart J, Souque A, Hellal-Lévy C, Wurtz JM, Moras D, Rafestin-Oblin ME.

Mol Pharmacol. 2000 Oct;58(4):684-91.

PMID:
10999937
28.

Crucial role of the H11-H12 loop in stabilizing the active conformation of the human mineralocorticoid receptor.

Hellal-Levy C, Fagart J, Souque A, Wurtz JM, Moras D, Rafestin-Oblin ME.

Mol Endocrinol. 2000 Aug;14(8):1210-21.

PMID:
10935545
29.

Mechanistic aspects of mineralocorticoid receptor activation.

Hellal-Levy C, Fagart J, Souque A, Rafestin-Oblin ME.

Kidney Int. 2000 Apr;57(4):1250-5. Review.

30.

[Corticosteroid hormones: mechanisms involved in the recognition of aldosterone by mineralocorticoid receptors].

Hellal-Levy C, Fagart J, Souque A, Rafestin-Oblin ME.

J Soc Biol. 1999;193(4-5):355-60. Review. French.

PMID:
10689617
31.

Specific hydroxylations determine selective corticosteroid recognition by human glucocorticoid and mineralocorticoid receptors.

Hellal-Levy C, Couette B, Fagart J, Souque A, Gomez-Sanchez C, Rafestin-Oblin M.

FEBS Lett. 1999 Dec 24;464(1-2):9-13.

32.

Corticosteroid-dependent sodium transport in a novel immortalized mouse collecting duct principal cell line.

Bens M, Vallet V, Cluzeaud F, Pascual-Letallec L, Kahn A, Rafestin-Oblin ME, Rossier BC, Vandewalle A.

J Am Soc Nephrol. 1999 May;10(5):923-34.

33.

Conformational change in the human glucocorticoid receptor induced by ligand binding is altered by mutation of isoleucine 747 by a threonine.

Roux S, Térouanne B, Couette B, Rafestin-Oblin ME, Nicolas JC.

J Biol Chem. 1999 Apr 9;274(15):10059-65.

34.

Photoaffinity labelling of the human mineralocorticoid receptor with steroids having a reactive group at position 3, 18 or 21.

Fagart J, Couette B, Souque A, Davioud E, Marquet A, Rafestin-Oblin ME.

Biochim Biophys Acta. 1998 Oct 14;1388(1):35-44.

PMID:
9774704
35.

[Aldosterone receptors: new insights in hormonal signal transduction].

Rafestin-Oblin ME, Couette B.

Therapie. 1998 May-Jun;53(3):227-35. Review. French.

PMID:
9773122
36.

Antagonism in the human mineralocorticoid receptor.

Fagart J, Wurtz JM, Souque A, Hellal-Levy C, Moras D, Rafestin-Oblin ME.

EMBO J. 1998 Jun 15;17(12):3317-25.

37.

Folding requirements of the ligand-binding domain of the human mineralocorticoid receptor.

Couette B, Jalaguier S, Hellal-Levy C, Lupo B, Fagart J, Auzou G, Rafestin-Oblin ME.

Mol Endocrinol. 1998 Jun;12(6):855-63.

PMID:
9626661
38.

Pleiotropic effects of dihydrotestosterone in immortalized mouse proximal tubule cells. Technical note.

Ouar Z, Solé E, Bens M, Rafestin-Oblin ME, Meseguer A, Vandewalle A.

Kidney Int. 1998 Jan;53(1):59-66.

40.

Cell-specific, promoter-dependent mineralocorticoid agonist activity of spironolactone.

Massaad C, Lombès M, Aggerbeck M, Rafestin-Oblin ME, Barouki R.

Mol Pharmacol. 1997 Feb;51(2):285-92.

PMID:
9203634
41.

New steroidal diazo ketones as potential photoaffinity labeling reagents for the mineralocorticoid receptor: synthesis and biological activities.

Davioud E, Fagart J, Souque A, Rafestin-Oblin ME, Marquet A.

J Med Chem. 1996 Jul 5;39(14):2860-4.

PMID:
8709117
42.

Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure.

Couette B, Fagart J, Jalaguier S, Lombes M, Souque A, Rafestin-Oblin ME.

Biochem J. 1996 Apr 15;315 ( Pt 2):421-7.

43.

Sulfhydryl groups are involved in the binding of agonists and antagonists to the human mineralocorticoid receptor.

Souque A, Fagart J, Couette B, Rafestin-Oblin ME.

J Steroid Biochem Mol Biol. 1996 Mar;57(5-6):315-21.

PMID:
8639467
44.

The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent.

Souque A, Fagart J, Couette B, Davioud E, Sobrio F, Marquet A, Rafestin-Oblin ME.

Endocrinology. 1995 Dec;136(12):5651-8.

PMID:
7588320
45.

The establishment of the long terminal repeat of the mouse mammary tumor virus into CV-1 cells allows a functional analysis of steroid receptors.

Couette B, Le Ricousse S, Fortin D, Rafestin-Oblin ME, Richard-Foy H.

Biochim Biophys Acta. 1994 Nov 22;1219(3):607-12.

PMID:
7948018
46.

The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase.

Lombes M, Kenouch S, Souque A, Farman N, Rafestin-Oblin ME.

Endocrinology. 1994 Sep;135(3):834-40.

PMID:
8070376
47.

Differential intracellular localization of human mineralocorticosteroid receptor on binding of agonists and antagonists.

Lombès M, Binart N, Delahaye F, Baulieu EE, Rafestin-Oblin ME.

Biochem J. 1994 Aug 15;302 ( Pt 1):191-7.

48.

Phenotypic effects of aldosterone and dexamethasone in a SV40-transformed mammalian cortical ascending limb cell line exhibiting mineralocorticoid receptors.

Vandewalle A, Rafestin-Oblin ME, Hagege J, Géniteau-Legendre M, Cassingéna R, Ronco PM.

J Cell Physiol. 1993 Aug;156(2):383-94.

PMID:
8393880
49.

Mineralocorticoid receptors in SV40-transformed tubule cell lines derived from rabbit kidney.

Rafestin-Oblin ME, Farman N, Cassingena R, Ronco P, Vandewalle A.

J Steroid Biochem Mol Biol. 1993 Jan;44(1):45-52.

PMID:
8381014
50.

Aldosterone antagonists destabilize the mineralocorticosteroid receptor.

Couette B, Lombes M, Baulieu EE, Rafestin-Oblin ME.

Biochem J. 1992 Mar 15;282 ( Pt 3):697-702.

Supplemental Content

Loading ...
Support Center